CI

ACCE-researched
The Cigna Group Common Stock
Healthcare · Healthcare Plans · NYSE · United States
$275.28-0.26%
Market cap $72.7BNext earnings 2026-10-29Updated Sep 21, 2026
FAIR VALUE · CONSENSUS
$275.28+0.0%
confidence-weighted across 4 of 6 models
Now $275.28
$275.28
$282.06$1167.14
Strong BuySilver73
Price vs fair value
30.6% below
+44.0% to fair value
ACCE score
61
out of 100
Analysts
76% buy
25 covering
P/E
11.4x
forward 8.2x
1-year return
-6.3%
Dividend yield
2.22%
Unlock the ACCE read
INVESTOR

Overview

ACCE thesis

Cigna runs two distinct businesses - Evernorth, a pharmacy benefit management and specialty drug services platform generating roughly 60% of total revenue, and Cigna Healthcare, a commercial and government health insurance operation - and the market is pricing them as if they're the same broken managed care story. Evernorth's Express Scripts gives Cigna formulary leverage and data scale that pure-play insurers can't replicate, and specialty pharmacy volumes tied to GLP-1 dispensing are running ahead of most estimates. The near-term catalyst is the company's ongoing evaluation of its Medicare Advantage exit, which should sharpen earnings quality and remove the segment that's been the primary drag on sentiment across the entire managed care group. At 8.5x forward earnings against a 16.3% ROE, the market is discounting Evernorth's durable cash generation as if the insurance losses are permanent - they're not. When MA headwinds lap in 2026 and Evernorth's specialty volumes are disaggregated from the noise, the multiple compression that's hit CI harder than peers looks like a misread worth owning.

Written May 18, 2026
Investor warnings · 4 flags
  • severe
    ACCE score collapse
    Score dropped 27 points in 90 days (91→64), signaling rapid fundamental or sentiment deterioration requiring immediate investigation.
  • high
    Heavy insider selling
    Last 10 disclosed transactions show $59.11M in sales, zero buys - concentrated distribution at current prices.
  • high
    Quarterly revenue deceleration
    QoQ revenue growth of -5.5% contrasts with +4.6% YoY, suggesting recent business momentum has sharply reversed.
  • moderate
    Razor-thin net margin
    Net margin of only 2.3% leaves minimal buffer; any cost spike or reimbursement pressure could eliminate profitability quickly.
Reports in 37 days, last quarter beat by 0.0%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

-4.6% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish76% buy · 25 covering analysts
Strong buy 13 Buy 6 Hold 6 Sell 0 Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 83% of peers
low 0.0x11.4xhigh 1254.9x
ROEbetter than 100% of peers
low -20%17%high 17%
Div yieldbetter than 67% of peers
low 0.0%2.2%high 2.9%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
ELVElevance Health Inc. Common Stock$89.1B18.211.1%0.731.7%-Compare
CVSCVS Health Corporation Common Stock$113.6B23.46.2%0.862.9%-Compare
HUMHumana Inc. Common Stock$46.4B36.56.9%0.700.9%-Compare
CNCCentene Corporation Common Stock$32.2B--20.4%0.870.0%-Compare
UNHUnitedHealth Group Incorporated Common Stock (DE)$338.3B24.214.1%0.832.4%-Compare
MOHMolina Healthcare Inc Common Stock$10.5B1254.9-0.2%0.930.0%-Compare

Sector report card

Where CI ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 37 days, last quarter beat by 0.0%.

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
-2.0%
1 month
-0.8%
3 months
-1.4%
6 months
+4.7%
YTD
+0.0%
1 year
-6.3%

SEC filings

40 filings
September 2026
Sep 8
Form 4Insider transactionPeriod 2026-09-03
Sep 3
Form 4Insider transactionPeriod 2026-09-01
Sep 2
Form 4Insider transactionPeriod 2026-08-31
37 more filings + AI summaries on Investor+.INVESTOR